Results 201 to 210 of about 16,868,271 (383)

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

A clinical medicine level test at Jinan University School of Medicine reveals the importance of training medical students in clinical history-taking. [PDF]

PeerJ, 2023
Meng X, Zhang M, Ma W, Cheng X, Yang X.
europepmc   +1 more source

THE CLINICAL COURSE OF PATIENTS WITH A HISTORY OF ACUTE PERICARDITIS FOLLOWING VACCINATION AGAINST SARS-COV2

, 2022
Yishay Wasserstrum, Sofia Nadav, Amitai Segev, Dor Lotan, Dov Freimark, Michael Arad   +5 more
openalex   +2 more sources

456 NATURAL HISTORY AND CLINICAL BURDEN OF MODERATE AORTIC STENOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS [PDF]

, 2022
Martina Morelli, Michele Galasso, Francesco Soriano, Stefano Nava, Caterina Da Pozzo, Giuseppe Esposito, Emanuela Piccaluga, Irene Bossi, Claudio Montalto, Jacopo Oreglia, Cristina Giannattasio   +10 more
openalex   +1 more source

Survivin and Aurora Kinase A control cell fate decisions during mitosis

Molecular Oncology, EarlyView.
Aurora A interacts with survivin during mitosis and regulates its centromeric role. Loss of Aurora A activity mislocalises survivin, the CPC and BubR1, leading to disruption of the spindle checkpoint and triggering premature mitotic exit, which we refer to as ‘mitotic slippage’.
Hana Abdelkabir, Shalitha Wickrama Arachchige, Sally P. Wheatley   +2 more
wiley   +1 more source

Using clinical history taking chatbot mobile app for clinical bedside teachings - A prospective case control study. [PDF]

Heliyon, 2022
Co M, John Yuen TH, Cheung HH.
europepmc   +1 more source

Endpoints and Design for Clinical Trials in USH2A-Related Retinal Degeneration: Results and Recommendations From the RUSH2A Natural History Study [PDF]

Maureen G. Maguire, David G. Birch, Jacque L. Duncan, Allison R. Ayala, Lauren N. Ayton, Janet K. Cheetham, Peiyao Cheng, Todd A. Durham, Frederick L. Ferris, Carel B. Hoyng, Rachel M. Huckfeldt, Glenn J. Jaffe, Christine N. Kay, Eleonora M. Lad, Bart Leroy, Wendi Liang, Lee S. McDaniel, Michele Melia, Michel Michaelides, Mark E. Pennesi, José-Alain Sahel, Lassana Samarakoon   +21 more
openalex   +1 more source

Clinical examination and patients’ history are not suitable for neonatal hip screening [PDF]

, 2022
Christian Ziegler, Katharina Maria Ertl, M. Delius, Kai Foerster, Alexander Crispin, Ferdinand Wagner, Bernhard Heimkes   +6 more
openalex   +1 more source

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

Query bot for retrieving patients' clinical history: A COVID-19 use-case. [PDF]

J Biomed Inform, 2021
Wang Y, Tariq A, Khan F, Gichoya JW, Trivedi H, Banerjee I.   +5 more
europepmc   +1 more source